Linked Life Data

9187180

Source:http://linkedlifedata.com/resource/pubmed/id/9187180

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1997-7-3
pubmed:abstractText
Twenty-one patients with malignant pleural effusion (MPE) were prospectively entered into a nonrandomized, single-armed study to evaluate the efficacy and safety of recombinant interferon (IFN) alpha-2b (INTRON A; Schering-Plough; Kenilworth, NJ) as an intrapleural palliative agent. From March 1989 through February 1993 (48 months), 21 patients were entered into the study. No symptomatic effusion recurred and no substantial side effects were associated with treatment. This suggests recombinant IFN alpha-2b represents a safe and effective intrapleural agent for the palliation of MPE.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0012-3692
pubmed:author
pubmed:issnType
Print
pubmed:volume
111
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1597-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Recombinant interferon alpha-2b in the management of malignant pleural effusions.
pubmed:affiliation
Department of Surgery, Columbus-Cabrini Medical Center, Chicago, USA.
pubmed:publicationType
Journal Article, Clinical Trial